Recent Updates
Recently added Catalysts

Upcoming Catalyst

Drug Pipeline Intelligence

Clinical Trial Results

Inside Trades

Options Data

News Section

Hedge Funds

Ownership Trends

Competitive Position

AbbVie Inc.

35 indications, side-by-side phase, drug & LoA

$224.95

-0.61 (-0.27%)

A 92Pipeline Score Fair Value Pharma · Commercial
Market Cap
380.57 B
EPS
2.03
P/E Ratio
106.24 $
Value Trade
1.23 B
SEC Financials
Q1 2026

  • Dilution Risk

    5%

  • Revenue

    15.00 B

  • R&D Expenses

    2.47 B

  • Operating CF

    3.83 B

  • Total Assets

    136.46 B

  • Total Liabilities

    136.46 B

  • Equity

    -6.66 B

  • D/E Ratio

    12,345

1.22 %
Week
5.13 %
1 Month
-4.15 %
3 Month
-6.44 %
6 Month
83.54 %
5 Year
482.97 %
All Time
Cash Data
Profitable

  • Cash Position

    9.39 B

  • Monthly Burn

    -

  • Runway

    12,345 mo

  • Burn Trend

    Stable

  • SEC Filing

    May 8, 2026
Overview
Volume
4.15 M
52 Week Range
181.73 - 244.81
% held by Insiders
0.12 %
% held by Institutions
76.14 %
Enterprise Value
444.08 B
Total Shares
1.77 B
Short %
1.31 %
Float Shares
1.77 B
Company Description
HQ: 1 NORTH WAUKEGAN ROAD, NORTH C...
Founded:2011
Employees:57,000
https://www.abbvie.com

locked

Upcoming Catalyst
Catalyst Drug/Treatment Stage Probability of Approval Description Drug Type Therapeutic Area Source
Phase 3 data readout example
venetoclax (VENCLEXTA®) Previously untreated Chronic Lymphocytic Leukemia (CLL)
Phase 3
—
Small Molecules
Oncology
venetoclax (VENCLEXTA®) Previously untreated Chronic Lymphocytic Leukemia (CLL)
Phase 3
—
Small Molecules
Oncology
venetoclax (VENCLEXTA®) Previously untreated Chronic Lymphocytic Leukemia (CLL)
Phase 3
—
Small Molecules
Oncology
Unlock Upcoming Catalyst data
Drug Pipeline Intelligence
A92
Pipeline Score
$96.4B
Pipeline Value
Fair Value
Valuation Signal
299
Drugs Scored
0.8x
rNPV / MCap
Top 99%
Large Pharma
(rank 10 of 905)
Percentile Rank
AbbVie Inc. earns an A-grade pipeline score (92/100), with $96.4B risk-adjusted pipeline value, led by MGd in Metastatic Cancer (Phase 3).
Showing 1 of 1 assets
DrugIndicationPhaseNCT IDPTRSrNPVStatusEnrollmentVelocityDesignCompletionML SignalLast Change
MGd
Small molecule		Metastatic CancerPhase 3NCT0000356346% $14.1B COMPLETED 430 - -Jun 1, 2005 -Oct 31, 2013
Unlock Drug Pipeline Intelligence
Clinical Trial Results
Drug Name Indications Phase Date Trial Results Summary Title Source
SKINVIVE by JUVÉDERM®
neck lines,improvement of neck appearance
Phase 2
2025-06-30
SKINVIVE by JUVÉDERM®
neck lines,improvement of neck appearance
Phase 2
2025-06-30
SKINVIVE by JUVÉDERM®
neck lines,improvement of neck appearance
Phase 2
2025-06-30
Unlock Clinical Trial Results data
Inside Trades
TREND
CORPORATE INSIDERS BOUGHT SHARES WORTH 1.8M IN THE LAST 3 MONTHS
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Unlock Inside Trades data
Show Data
Hedge Funds
TREND
HEDGE FUNDS INCREASED HOLDINGS BY 200.0K SHARES IN THE LAST QUARTER
Shares Held
2040.00B1530.00B1020.00B510.00B0
Q3
2024
Q4
2024
Q1
2025
Q2
2025
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Fund Count
60%
Share Volume
25%
Conviction
15%
Hedge Funds invested in ABBV
HedgeFund Name
( 3 )
% of Portfolio Current MV
-
Shares Owned
-
Activity
Avg Price $0

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K
Unlock Hedge Funds table data
Biotech Analyst Ratings
Symbol
Firm
Rating
Action
Price Target
Upside
date
ABBV
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
ABBV
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
ABBV
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
Unlock Biotech Analyst Ratings data
ABBV Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
Unlock Price Target Trend
ABBV Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
ExpirationVolumeOpen InterestImplied Volatility CallsImplied Volatility Puts
CallsPutsPut-Call RatioCallsPutsPut-Call RatioIVOiWaIvVWaIvIVOiWaIvVWaIv
2026-06-120 0.00 0 0 - - - - - -
2026-06-120 0.00 0 0 - - - - - -
2026-06-120 0.00 0 0 - - - - - -
Unlock Option Chain Statistics data
Option Chain
CallsStrikePuts
Last PriceVolumeOpen InterestLast PriceVolumeOpen Interest
No data available
Unlock Option Chain data
Unlock Options Chart data
Open interest
0 600K 1.2M 1.8M Avg OI 1.00 M Open Interest
0 1 2 3 1.1 Put-Call Ratio
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
0 450K 900K 1.4M Avg OV 750.00 K Option Volume
0 1 2 3 0.95 Put-Call Ratio
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Latest AbbVie Inc. (ABBV) News & Alerts
-
Thursday, June 11, 2026
(%)
+ More

Demo Biotech Announces Positive Phase 3 Results

Competitive Position
How ABBV ranks across every disease it competes in
Indication Rank Phase Best DrugTop 3 Competitors Market $B LoA Position
Colorectal Cancer #1 of 82 PHASE 3 Telisotuzumab Adizutecan
BMY MRK JNJ
$7.68B 0.88 LEADER
Rheumatoid Arthritis #1 of 28 PHASE 3 Upadacitinib + Adalimumab
LLY BMY JNJ
$4.2B 0.92 LEADER
Hidradenitis Suppurativa #1 of 13 PHASE 3 Lutikizumab
INCY NVS MLTX
$1.7B 0.91 LEADER
Migraine #1 of 5 PHASE 3 Atogepant
PFE LLY AMGN
$7.02B 0.95 LEADER
Age-Related Macular Degeneration #1 of 13 PHASE 3 Surabgene Lomparvovec + Ranibizumab Control
OCUL FDMT REGN
$15.43B 0.91 LEADER
Dry Eye Disease #1 of 7 PHASE 3 ABBV-444 + REFRESH OPTIVE UD
GRFS BLCO VNDA
$6.61B 0.93 LEADER
Reproductive Endocrine #1 of 7 PHASE 3 Elagolix + Combined Contraceptive
EDAP ABT ·dev MDT ·dev
—0.91 LEADER
Ocular Hypertension #1 of 4 PHASE 3 Bimatoprost
SGP AMRX GKOS
$9.41B 0.91 LEADER
Retinal Disorders #1 of 4 PHASE 2 ABBV-RGX-314 + Ranibizumab
PRQR ALC UBX
—0.91 LEADER
Polycystic Kidney Disease #1 of 3 PHASE 2 ABBV-CLS-628
VRTX AZN
$1.76B 0.88 LEADER
Multiple Myeloma #2 of 27 PHASE 3 Pomalidomide + Dexamethasone + Venetoclax
JNJ BMY TAK
$23.78B 0.88 LEADER
Atopic Dermatitis #2 of 25 PHASE 3 Upadacitinib + corticosteroids
LLY PFE SNY
$20.76B 0.92 LEADER
Myelodysplastic Syndromes #2 of 33 PHASE 3 Venetoclax + Azacitidine
BMY TAK ARGX
$2.5B 0.93 CONTENDER
Myeloproliferative Neoplasms #2 of 14 PHASE 3 Navitoclax + Ruxolitinib
BMY NVS KPTI
—0.84 CONTENDER
Psoriatic Arthritis #2 of 13 PHASE 3 Risankizumab
JNJ BMY TAK
—0.91 LEADER
Glaucoma #2 of 7 PHASE 3 Bimatoprost
GKOS SGP AMRX
$8.99B 0.92 CONTENDER
Bipolar Disorder #2 of 12 PHASE 3 Cariprazine
BMY ALKS XENE
$10.5B 0.91 CONTENDER
Irritable Bowel Syndrome #2 of 6 PHASE 3 Eluxadoline
ARDX IRON TAK
$1.44B 0.91 CONTENDER
Diabetic Retinopathy #2 of 5 PHASE 2 ABBV-RGX-314 Dose 1 + Steroid + Aflibercept
OCUL FDMT RYTM
$10.29B 0.95 CONTENDER
Crohn's Disease #3 of 15 PHASE 3 Risankizumab + Risankizumab On-Body Injector
SNY LLY JNJ
$12.67B 0.91 LEADER
Psoriasis #3 of 15 PHASE 3 Risankizumab
JNJ BMY TAK
$26.66B 0.95 CONTENDER
Alopecia #3 of 12 PHASE 3 Upadacitinib
PFE MANE LLY
$10.76B 0.91 CONTENDER
Vasculitis #3 of 16 PHASE 3 Upadacitinib + Prednisolone
AZN GSK AMGN
$2.5B 0.85 CONTENDER
Vitiligo #3 of 8 PHASE 3 Upadacitinib
INCY PFE TAK
$1.2B 0.93 CONTENDER
Open-Angle Glaucoma #3 of 5 PHASE 4 Bimatoprost
GKOS AMRX UTHR
$8.99B 0.93 CONTENDER
Ovarian Cancer #4 of 61 PHASE 3 Mirvetuximab soravtansine plus Bevacizumab + Bevacizumab
MRK AZN LLY
$4.0B 0.86 LEADER
Ulcerative Colitis #4 of 17 PHASE 3 Upadacitinib
SNY JNJ LLY
$6.5B 0.9 LEADER
Major Depressive Disorder #4 of 31 PHASE 3 Cariprazine
CMPS NBIX JNJ
$12.0B 0.94 CONTENDER
Anxiety Disorders #4 of 12 PHASE 2 ABBV-932 + Antidepressant Therapy
DFTX VTGN VNDA
—0.95 CONTENDER
Idiopathic Pulmonary Fibrosis #4 of 12 PHASE 2 ABBV-142
BMY UTHR PRTC
$4.87B 0.95 CONTENDER
Diabetic Macular Edema #4 of 11 PHASE 2 ABBV-RGX-314 Dose 1 + Steroid + Aflibercept
EYPT REGN OCS
$4.2B 0.95 CONTENDER
Geographic Atrophy #5 of 8 PHASE 1 ABBV-6628 + SYFOVRE
REGN BLTE ANNX
$2.12B 0.91 CONTENDER
Non-Small Cell Lung Cancer #6 of 88 PHASE 3 Telisotuzumab Vedotin + Docetaxel
MRK AMGN AZN
$28.1B 0.87 LEADER
Leukemia #6 of 64 PHASE 3 Venetoclax
AMGN LLY AZN
$4.28B 0.89 LEADER
Pancreatic Cancer #6 of 73 PHASE 2 TTX-030, nab-paclitaxel and gemcitabine + Nab-Paclitaxel and gemcitabine
RVMD RCUS AZN
$3.7B 0.82 CONTENDER
Liver Cancer #6 of 37 PHASE 2 Budigalimab + Livmoniplimab + Lenvatinib + Sorafenib
AZN BMY EXEL
$4.8B 0.85 CONTENDER
Systemic Lupus Erythematosus #6 of 32 PHASE 3 Upadacitinib
BIIB VTRS BMY
$2.78B 0.88 CONTENDER
Thyroid Disorders #6 of 11 PHASE 2 Armour Thyroid + Levothyroxine
VRDN AMGN ZLAB
$11.1B 0.91 FOLLOWER
Lung Cancer #8 of 79 PHASE 3 ABBV-706 + Topotecan + Lurbinectedin + Amrubicin
MRK GILD AMGN
$28.1B 0.89 LEADER
Esophageal Cancer #8 of 39 PHASE 2 Telisotuzumab Adizutecan + Budigalimab + Fluorouracil + Leucovorin + Oxaliplatin
MRK AZN ONC
$1.85B 0.85 CONTENDER
Schizophrenia #8 of 15 PHASE 2 Emraclidine
NBIX BMY ALKS
$2.5B 0.95 FOLLOWER
Amyloidosis #8 of 11 PHASE 1 ABBV-383
AZN NTLA JNJ
$5.17B 0.89 FOLLOWER
Lymphoma #9 of 69 PHASE 3 Venetoclax
REGN LLY MRK
$8.52B 0.83 CONTENDER
Gastric Cancer #10 of 49 PHASE 2 Telisotuzumab Adizutecan + Budigalimab + Fluorouracil + Leucovorin + Oxaliplatin
AZN ONC JAZZ
$6.74B 0.88 FOLLOWER
Cervical Cancer #12 of 31 PHASE 1 IMGN151
AZN MRK PFE
$2.8B 0.85 FOLLOWER
Obesity #19 of 33 PHASE 1 ABBV-295
LLY AMGN NVO
$22.52B 0.97 FOLLOWER
Bladder Cancer #19 of 47 PHASE 2 Livmoniplimab + Budigalimab + Docetaxel + Paclitaxel + Gemcitabine
AZN BMY JNJ
$0.33B 0.9 FOLLOWER
Endometrial Cancer #21 of 48 PHASE 1 IMGN151
MRK AZN GILD
$31.09B 0.85 FOLLOWER
Prostate Cancer #22 of 53 PHASE 1 ABBV-969
MRK AZN PFE
$25.12B 0.9 FOLLOWER
Head and Neck Cancer #22 of 63 PHASE 1 ABBV-400 + Itraconazole
AZN GSK MRK
$10.2B 0.8 FOLLOWER
Breast Cancer #27 of 94 PHASE 1 ABBV-400 + Itraconazole
MRK AZN GILD
$10.85B 0.84 FOLLOWER